# SPINRAZA Clinical Trial Data
Keywords: SPINRAZA, SMA, 5q SMA, ENDEAR study, infantile-onset SMA, motor milestones, survival, safety, Phase III study

> This page provides detailed clinical trial data for SPINRAZA, focusing on its efficacy and safety in treating infantile-onset spinal muscular atrophy (SMA), particularly Type I, based on the ENDEAR study.

## Details
- [Overview](#): SPINRAZA improves event-free survival and overall survival in patients with infantile-onset SMA.
- [Study Description](#): ENDEAR was a Phase III, randomized, double-blind, sham procedure-controlled study involving 121 symptomatic infants with SMA.
- [Motor Milestones](#): Highlights improvements in motor milestones for SPINRAZA-treated patients compared to sham-control patients.
- [Survival Outcomes](#): SPINRAZA demonstrated significant benefits in event-free and overall survival rates.
- [Safety Outcomes](#): Detailed safety data and adverse event reporting guidelines for SPINRAZA.
- [References](#): List of supporting studies and publications related to SPINRAZA and the ENDEAR trial.